Press Release Details

View all news

Researchers Reveal UK Trends in Inflammatory Eye Disease


Scleritis is a vision-threatening inflammatory condition of the white portion of the eye, or the sclera, that is thought to be the result of an over-reaction of the body’s immune system. A new study published in Arthritis & Rheumatology provides estimates of the incidence and prevalence of scleritis between 1997 and 2018 in the U.K.

Investigators found that the U.K. incidence of new cases appears to have fallen by about one-third over the past 22 years, to 2.8 new cases per 100,000 people per year. This trend is likely due to improvements in the management of immune-related diseases. Individuals who developed scleritis often had immune-related diseases before or after being diagnosed with scleritis.

“This study highlights how the use of routinely collected large-scale data offers unprecedented opportunity to advance understanding of the epidemiology of rare conditions and their associations,” the authors wrote.

Additional Information

Link to Study:

About Journal

Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer-reviewed publication for scientists and clinicians interested in the natural history, pathophysiology, treatment, and outcome of the rheumatic diseases. Arthritis & Rheumatology publishes the highest quality basic and clinical research related to the rheumatic diseases, encompassing a wide range of areas of investigative activity. In addition, the journal publishes review articles, editorials, and other educational material intended for both researchers and clinicians. Serving the worldwide community of rheumatology investigators and clinicians, Arthritis & Rheumatology is known internationally as a top rheumatology research journal.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at

Multimedia Files:

View all news